Recent administrative actions have shaped expectations around the timeline for full DEA rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. A December 2025 executive order directed expedited rulemaking, leading to an April 2026 order that immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III. Formal hearings on broader rescheduling ran from June 29 to July 15, 2026, with post-hearing briefs due August 17. The process now moves to an administrative law judge recommendation and potential final agency action, subject to procedural requirements and possible appeals. These steps, alongside any legislative or court developments, represent the primary near-term catalysts for resolution dates in the prediction market.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया$796,429 वॉल्यूम
30 मार्च, 2026
30 सितंबर
21%
31 दिसंबर
27%
$796,429 वॉल्यूम
30 सितंबर
$0 वॉल्यूम
21%
31 दिसंबर
$186,858 वॉल्यूम
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent administrative actions have shaped expectations around the timeline for full DEA rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. A December 2025 executive order directed expedited rulemaking, leading to an April 2026 order that immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III. Formal hearings on broader rescheduling ran from June 29 to July 15, 2026, with post-hearing briefs due August 17. The process now moves to an administrative law judge recommendation and potential final agency action, subject to procedural requirements and possible appeals. These steps, alongside any legislative or court developments, represent the primary near-term catalysts for resolution dates in the prediction market.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
बाज़ार खुला: Feb 7, 2026, 5:04 PM ET
वॉल्यूम
$796,429समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent administrative actions have shaped expectations around the timeline for full DEA rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. A December 2025 executive order directed expedited rulemaking, leading to an April 2026 order that immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III. Formal hearings on broader rescheduling ran from June 29 to July 15, 2026, with post-hearing briefs due August 17. The process now moves to an administrative law judge recommendation and potential final agency action, subject to procedural requirements and possible appeals. These steps, alongside any legislative or court developments, represent the primary near-term catalysts for resolution dates in the prediction market.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
वॉल्यूम
$796,429समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent administrative actions have shaped expectations around the timeline for full DEA rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. A December 2025 executive order directed expedited rulemaking, leading to an April 2026 order that immediately moved FDA-approved products and state-licensed medical marijuana to Schedule III. Formal hearings on broader rescheduling ran from June 29 to July 15, 2026, with post-hearing briefs due August 17. The process now moves to an administrative law judge recommendation and potential final agency action, subject to procedural requirements and possible appeals. These steps, alongside any legislative or court developments, represent the primary near-term catalysts for resolution dates in the prediction market.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न